NFIB has also been implicated in models of small‐cell lung carcinoma (SCLC) and breast cancer (Moon et al,2011; Denny et al,2016; Semenova et al,2016; Campbell et al,2018; Liu et al,2019), and NFIB or ERO1A has been associated with different tumour types (Becker‐Santos et al,2017; Zhou et al,2017; Yang et al,2018). This evidence concerns the gene ERO1A and breast carcinoma.